NexMed Gets Cash Infusion of $750K
NEXM | Quote | Chart | News | PowerRating -- NexMed, Inc., a developer of transdermal products based on the NexACT drug delivery technology, announced that it raised $750,000 in gross proceeds from the issuance of new convertible notes due December 31, 2011, which are secured by a mortgage on NexMed's facility in East Windsor, New Jersey.
The Company said that the notes were purchased by two investors, including The Tail Wind Fund, a long term investor in NexMed.
The Notes are convertible into shares of NexMed common stock at $2 per share with a coupon rate of 7 percent per annum. The shares underlying the Notes will not be registered with the Securities and Exchange Commission.
((Comments on this story may be sent to health@closeupmedia.com))
For full details on Nexmed Inc (NEXM) NEXM. Nexmed Inc (NEXM) has Short Term PowerRatings at TradingMarkets. Details on Nexmed Inc (NEXM) Short Term PowerRatings is available at This Link.
- BiomedReports: News and FDA Updates for Lannett (NYSE:LCI), MWI (NASDAQ:MWIV), NexMed (Nasdaq:NEXM) - 02/09/10
- Liberty Analytics Co. Initiates Independent Research Coverage on NexMed, Inc. - 02/09/10
- NexMed Inc reports cash infusion of over USD2.7m - 02/09/10
- NexMed Receives over $2.7 Million Cash Infusion - 02/08/10
- BiomedReports: News and FDA Updates for Mentor Capital (OTC:MNTR), NexMed (Nasdaq:NEXM), Onyx (Nasdaq:ONXX) - 02/02/10
- More News >>


